A review of minodronic acid hydrate for the treatment of osteoporosis

Figures & data

Table 1 Clinical studies of minodronate acid hydrate in osteoporosis

Author and year of publication	Hagino et al^Citation12 (2009)	Matsumoto et al^Citation13 (2009)	Ito et al^Citation14 (2010)	Okazaki et al^Citation15 (2012)
Study population	n = 270	n = 704	n = 103	n = 692
	Minod n = 135	Minod n = 359		Minod (1) n = 203
	Alend n = 135	Placebo n = 345		Minod (30) n = 209
				Minod (50) n = 229
Patients	≥45 years	>55 years	>45 years	51–89 years
	Postmenopausal	Postmenopausal	Postmenopausal	Postmenopausal women and men
Follow-up (months) Assessment	12	24	12	12
	Bone mineral density	Vertebral fractures	Bone mineral density	Bone mineral density
	Lumbar spine: hip	Bone turnover marker	Lumbar spine: hip	Lumbar spine: hip
	Bone turnover marker		Bone geometry	Vertebral fractures
			Bone-strength indices: femur	Nonvertebral fractures
Drug Comparators	Minod 1 mg daily	Minod 1 mg daily	Minod 1 mg daily	Minod 50 mg monthly
	Alend 5 mg daily	Placebo	–	Minod 1 mg daily
				Minod 30 mg/month

Copyright © 2010. Prous Science, SAU or its licensors. All rights reserved. Adapted with permission from Kubo T, Shimose S, Matsuo T, Fujimori J, Ochi M. Minodronate for the treatment of osteoporosis. Drugs of Today (Barc). 2010;46(1):33–37.

Abbreviations: Minod, minodronate hydrate acid; Alend, alendronate acid.

HaginoHNishizawaYSoneTA double-blinded head-to-head trial of minodronate and alendronate in women with postmenopausal osteoporosisBone20094461078108419264155

 PubMed Web of Science ®Google Scholar

MatsumotoTHaginoHShirakiMEffect of daily oral minodronate on vertebral fractures in Japanese postmenopausal women with established osteoporosis: a randomized placebo-controlled double-blind studyOsteoporos Int20092081429143719101754

 PubMed Web of Science ®Google Scholar

ItoMSoneTFukunagaMEffect of minodronic acid hydrate on hip geometry in Japanese women with postmenopausal osteoporosisJ Bone Miner Metab201028333434119937358

 PubMed Web of Science ®Google Scholar

OkazakiRHaginoHItoMEfficacy and safety of monthly oral minodronate in patients with involutional osteoporosisOsteoporos Int20122361737174521932114

 PubMed Web of Science ®Google Scholar